Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 4% Following Analyst Upgrade

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s share price rose 4% on Monday after UBS Group raised their price target on the stock from $331.00 to $349.00. UBS Group currently has a buy rating on the stock. Alnylam Pharmaceuticals traded as high as $271.09 and last traded at $269.86. Approximately 287,770 shares were traded during trading, a decline of 67% from the average daily volume of 884,542 shares. The stock had previously closed at $259.39.

A number of other equities analysts also recently commented on the company. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. Royal Bank of Canada upped their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Finally, Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,392 shares of company stock valued at $1,875,627. Company insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $28,000. Whipplewood Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 3.4 %

The company has a market cap of $34.89 billion, a price-to-earnings ratio of -124.76 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The business's 50 day simple moving average is $248.21 and its 200-day simple moving average is $254.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. The business's quarterly revenue was up 20.2% on a year-over-year basis. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.